Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF

American Heart Journal

Volumn 162, Issue 4, 2011, Pages

  Piccini, Jonathan P ^a   Fraulo, Elizabeth S ^a   Ansell, Jack E ^b   Fonarow, Gregg C ^c   Gersh, Bernard J ^d   Go, Alan S ^e   Hylek, Elaine M ^f   Kowey, Peter R ^g   Mahaffey, Kenneth W ^a   Thomas, Laine E ^a   Kong, Melissa H ^a   Lopes, Renato D ^a   Mills, Roger M ^h   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LENOX HILL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; DISEASE REGISTRY; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION; OUTPATIENT; PATIENT SATISFACTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; STROKE;

EID: 80053625958     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.07.001     Document Type: Article

References (44)

1. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125 (Pubitemid 44420743)
2. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive summary: a report of the ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines J Am Coll Cardiol 48 2006 854 906
3. L. Kilander, B. Andren, and H. Nyman Atrial fibrillation is an independent determinant of low cognitive function: A cross-sectional study in elderly men Stroke 29 1998 1816 1820 (Pubitemid 28399970)
4. T.J. Wang, M.G. Larson, and D. Levy Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 2003 2920 2925 (Pubitemid 36736633)
5. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
6. W.C. Lee, G.A. Lamas, and S. Balu Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective J Med Econ 11 2008 281 298
7. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
8. S.H. Hohnloser, H.J. Crijns, and M. van Eickels Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 2009 668 678
9. Mahaffey KW. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). American Heart Association Scientific Sessions; November 15, 2010; Chicago.
10. P.S. Douglas, J.M. Brennan, and K.J. Anstrom Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the ACC-National Cardiovascular Data Registry J Am Coll Cardiol 53 2009 1629 1641
11. M. Gheorghiade, and G. Filippatos Reassessing treatment of acute heart failure syndromes: the ADHERE registry Eur Heart J 7 2005 B13 19
12. N.A. Estes III, J.L. Halperin, and H. Calkins ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the ACC/AHA Task Force on Performance Measures and the Physician Consortium for Performance Improvement Circulation 117 2008 1101 1120
13. L.S. Wann, A.B. Curtis, and C.T. January ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the ACC/AHA Task Force on Practice Guidelines Circulation 123 2011 104 123
14. S.C. Chow, M. Chang, and A. Pong Statistical consideration of adaptive methods in clinical development J Biopharm Stat 15 2005 575 591 (Pubitemid 40967300)
15. H. Calkins, J. Brugada, and D.L. Packer HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures, and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Heart Rhythm 4 2007 816 861 (Pubitemid 46850611)
16. The ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
17. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
18. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694 (Pubitemid 41647882)
19. J. Spertus, P. Dorian, and R. Bubien Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire in patients with atrial fibrillation Circ Arrhythm Electrophysiol 4 2011 15 25
20. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2009 263 272
21. R. Pisters, D.A. Lane, and R. Nieuwlaat A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
22. A.S. Go, E.M. Hylek, and Y. Chang Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692 (Pubitemid 37475596)
23. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
24. E.M. Hylek, C. Evans-Molina, and C. Shea Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696 (Pubitemid 46842784)
25. Institute of Medicine Initial national priorities for comparative effectiveness research 2009 The National Academies Press Washington, DC
26. P.R. Kowey, J.A. Reiffel, and R. Myerburg Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS registry) Am J Cardiol 105 2010 1130 1134
27. M.C. Fang, A.S. Go, and Y. Chang Warfarin discontinuation after starting warfarin for atrial fibrillation Circ Cardiovasc Qual Outcomes 3 2010 624 631
28. P.G. Steg The Realise AF registry: an international, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of atrial fibrillation patients 2010 European Society of Cardiology Congress Stockholm
29. J.Y. Le Heuzey, G. Breithardt, and J. Camm The Record-AF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation Am J Cardiol 105 2010 687 693
30. R. Nieuwlaat, M.H. Prins, and J.Y. Le Heuzey Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation Eur Heart J 29 2008 1181 1189 (Pubitemid 351844895)
31. R. Nieuwlaat, A. Capucci, and A.J. Camm Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation Eur Heart J 26 2005 2422 2434 (Pubitemid 41552972)
32. A.S. Go, E.M. Hylek, and L.H. Borowsky Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934 (Pubitemid 30005032)
33. J.P. Piccini, R.D. Lopes, and K.W. Mahaffey Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation Curr Opin Cardiol 25 2010 312 320
34. D.R. Holmes, V.Y. Reddy, and Z.G. Turi Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial Lancet 374 2009 534 542
35. M.N. Khan, P. Jais, and J. Cummings Pulmonary-vein isolation for atrial fibrillation in patients with heart failure N Engl J Med 359 2008 1778 1785
36. I.C. Van Gelder, H.F. Groenveld, and H.J. Crijns Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 2010 1363 1373
37. Institute of Medicine Crossing the quality chasm: a new health system for the 21st century 2001 The National Academies Press Washington, DC
38. P. Dorian, W. Jung, and D. Newman The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy J Am Coll Cardiol 36 2000 1303 1309
39. G. Thrall, D. Lane, and D. Carroll Quality of life in patients with atrial fibrillation: a systematic review Am J Med 119 2006 e441 e448
40. D.B. Matchar, A. Jacobson, and R. Dolor Effect of home testing of international normalized ratio on clinical events N Engl J Med 363 2010 1608 1620
41. M.P. Muller, and A.S. Detsky Public reporting of hospital hand hygiene compliance-helpful or harmful? JAMA 304 2010 1116 1117
42. L. Curtis, A. Hernandez, and M. Greiner Validity of a national heart failure quality of care registry: comparison of Medicare patients in OPTIMIZE-HF versus non-OPTIMIZE-HF hospitals Circulation 115 2007 e595
43. P.A. Heidenreich, and G.C. Fonarow Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts Am Heart J 152 2006 935 939 (Pubitemid 44632955)
44. C.B. Granger, and B.J. Gersh Clinical trials and registries in cardiovascular disease: competitive or complementary? Eur Heart J 31 2010 520 521